Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07229625 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

StatusRecruiting
PhasePhase 3
Started2026-01-21
View on ClinicalTrials.gov ↗

Amendment history

2026-01-27
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-11→confirmed 2026-01-21
Study sitesdetails revised at 1 of 1 site
2025-11-13
Original filing
This study is a randomized, open-label, multicenter phase III clinical trial, aiming to evaluate the efficacy and safety of SHR-8068 combined with adbelimab and platinum-based chemotherapy in contrast to varicumab combined with platinum-based chemotherapy in the first-line treatment of patients with advanced BTC.
Trial Details
NCT Number NCT07229625
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Advanced Biliary Tract Cancer
Enrollment 604 participants
Start Date 2026-01-21
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-28